Sun Faces Higher Cost In Challenge Of Wyeth’s $960 Million Patent Claim
This article was originally published in PharmAsia News
Executive Summary
Sun Pharma could opt for an out-of-court settlement of U.S.-based Wyeth’s claim of $960 million in damages rather than face a court case that could end up costing the Indian drug maker even more if carried to the end.